Lanthanum carbonate: safety data after 10 years

Lanthanum carbonate: safety data after 10 years

Despite 10 years of post-marketing safety monitoring of the phosphate binder lanthanum carbonate, concerns about aluminium-like accumulation and toxicity persist. Here, we present a concise overview of the safety profile of lanthanum carbonate and interim results from a 5-year observational database study (SPD405-404; ClinicalTrials.gov identifier: NCT00567723). The pharmacokinetic paradigms of...

Lanthanum carbonate

Encephalopathy caused by lanthanum carbonate

Lanthanum carbonate is a nonaluminum, noncalcium phosphate-binding agent, which is widely used in patients with end-stage chronic kidney disease. Until now, no significant side-effects have been described for the clinical use of lanthanum carbonate, and there are no available clinical data regarding its tissue stores. Here we report the case of a 59-year-old patient who was admitted with confus...

Patient Safety at 10 Years

Throughout our specialty—at meetings, in our journals, and in our clinics—patient safety has become not only a buzzword but an important focus for plastic surgeons. The cover of this month’s Aesthetic Surgery Journal bears a banner reminding us that 2011 marks the 10th anniversary of the first dedicated instructional course in patient safety at the American Society for Aesthetic Plastic Surgery...

Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.

Calciphylaxis is a rare and debilitating vasculopathy predominantly seen in patients with renal failure. The proposed mechanism of injury is active vascular calcification with associated elevated parathyroid hormone, hypercalcemia, or hyperphosphatemia. With improved pharmacologic agents including non-calcium containing phosphate binders, vitamin D analogues, calcimimetics, and bisphosphonates,...